(Q36740517)

16 August 2017

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma (English)

1 reference

16 August 2017

1 reference

15

Henry S Friedman

1 reference

16 August 2017

8

Sridharan Gururangan

1 reference

16 August 2017

3

Annick Desjardins

1 reference

16 August 2017

1

David A Reardon

1 reference

16 August 2017

10

Roger E McLendon

1 reference

16 August 2017

14

Patrick Y Wen

1 reference

16 August 2017

4

James J Vredenburgh

1 reference

16 August 2017

9

Katherine B Peters

1 reference

16 August 2017

6

April Coan

1 reference

16 August 2017

5

James E Herndon

1 reference

16 August 2017

11

Julie A Norfleet

1 reference

16 August 2017

12

Eric S Lipp

1 reference

16 August 2017

Andrew D Norden

2

1 reference

16 August 2017

John H Sampson

series ordinal

7

1 reference

16 August 2017

Jan Drappatz

series ordinal

13

1 reference

16 August 2017

22 September 2011

1 reference

Journal of Neuro-Oncology

16 August 2017

1 reference

16 August 2017

106

1 reference

16 August 2017

2

1 reference

16 August 2017

409-415

1 reference

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Aberrant signaling pathways in meningiomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Pathological classification and molecular genetics of meningiomas.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Intracranial meningiomas of atypical (WHO grade II) histology

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

A review of malignant meningiomas: diagnosis, characteristics, and treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Hydroxyurea chemotherapy in the treatment of meningiomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Salvage chemotherapy with CPT-11 for recurrent meningioma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Temozolomide for treatment-resistant recurrent meningioma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Mifepristone (RU 486) treatment of meningiomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Control of meningioma cell growth by platelet-derived growth factor (PDGF).

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Non-resectable slow-growing meningiomas treated by hydroxyurea

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Treatment of high risk or recurrent meningiomas with hydroxyurea

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Response criteria for phase II studies of supratentorial malignant glioma

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3616615

Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings

5 September 2018

1 reference

12 December 2020

Platelet-derived growth factor expression and stimulation in human meningiomas

1 reference

12 December 2020

Platelet-derived growth factor (PDGF) and receptor (PDGFR) expression in human meningiomas: correlations with clinicopathological features and cytogenetic analysis

1 reference

12 December 2020

Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop

1 reference

12 December 2020

Expression of PDGF, PDGF-receptor, EGF-receptor and sex hormone receptors on meningioma

1 reference

12 December 2020

Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor

1 reference

12 December 2020

Hydroxyurea chemotherapy for unresectable or residual meningioma

1 reference

12 December 2020

Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas

1 reference

12 December 2020

Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series

1 reference

12 December 2020

10.1007/S11060-011-0687-1

Identifiers

DOI

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

21938530

1 reference